Unknown

Dataset Information

0

A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy.


ABSTRACT: Natural killer (NK) cells are a promising cellular therapy for cancer, with challenges in the field including persistence, functional activity, and tumor recognition. Briefly, priming blood NK cells with recombinant human (rh)IL-12, rhIL-15, and rhIL-18 (12/15/18) results in memory-like NK cell differentiation and enhanced responses against cancer. However, the lack of available, scalable Good Manufacturing Process (GMP)-grade reagents required to advance this approach beyond early-phase clinical trials is limiting. To address this challenge, we developed a novel platform centered upon an inert tissue factor scaffold for production of heteromeric fusion protein complexes (HFPC). The first use of this platform combined IL-12, IL-15, and IL-18 receptor engagement (HCW9201), and the second adds CD16 engagement (HCW9207). This unique HFPC expression platform was scalable with equivalent protein quality characteristics in small- and GMP-scale production. HCW9201 and HCW9207 stimulated activation and proliferation signals in NK cells, but HCW9207 had decreased IL-18 receptor signaling. RNA sequencing and multidimensional mass cytometry revealed parallels between HCW9201 and 12/15/18. HCW9201 stimulation improved NK cell metabolic fitness and resulted in the DNA methylation remodeling characteristic of memory-like differentiation. HCW9201 and 12/15/18 primed similar increases in short-term and memory-like NK cell cytotoxicity and IFNγ production against leukemia targets, as well as equivalent control of leukemia in NSG mice. Thus, HFPCs represent a protein engineering approach that solves many problems associated with multisignal receptor engagement on immune cells, and HCW9201-primed NK cells can be advanced as an ideal approach for clinical GMP-grade memory-like NK cell production for cancer therapy.

SUBMITTER: Becker-Hapak MK 

PROVIDER: S-EPMC8416787 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy.

Becker-Hapak Michelle K MK   Shrestha Niraj N   McClain Ethan E   Dee Michael J MJ   Chaturvedi Pallavi P   Leclerc Gilles M GM   Marsala Lynne I LI   Foster Mark M   Schappe Timothy T   Tran Jennifer J   Desai Sweta S   Neal Carly C CC   Pence Patrick P   Wong Pamela P   Wagner Julia A JA   Russler-Germain David A DA   Zhu Xiaoyun X   Spanoudis Catherine M CM   Gallo Victor L VL   Echeverri Christian A CA   Ramirez Laritza L LL   You Lijing L   Egan Jack O JO   Rhode Peter R PR   Jiao Jin-An JA   Muniz Gabriela J GJ   Jeng Emily K EK   Prendes Caitlin A CA   Sullivan Ryan P RP   Berrien-Elliott Melissa M MM   Wong Hing C HC   Fehniger Todd A TA  

Cancer immunology research 20210709 9


Natural killer (NK) cells are a promising cellular therapy for cancer, with challenges in the field including persistence, functional activity, and tumor recognition. Briefly, priming blood NK cells with recombinant human (rh)IL-12, rhIL-15, and rhIL-18 (12/15/18) results in memory-like NK cell differentiation and enhanced responses against cancer. However, the lack of available, scalable Good Manufacturing Process (GMP)-grade reagents required to advance this approach beyond early-phase clinica  ...[more]

Similar Datasets

| S-EPMC8889352 | biostudies-literature
2022-02-02 | GSE166268 | GEO
| S-EPMC10413107 | biostudies-literature
2020-08-25 | GSE154694 | GEO
2021-04-15 | GSE172100 | GEO
| S-EPMC9374793 | biostudies-literature
| S-EPMC2909391 | biostudies-literature
| S-EPMC4687420 | biostudies-literature
| S-EPMC5890538 | biostudies-literature
| S-EPMC9612852 | biostudies-literature